The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| NPCE | +49.44% | N/A | N/A | -62% |
| S&P | +19.61% | +98.99% | +14.75% | +66% |
NeuroPace, Inc. develops, manufactures, and markets implantable devices for treating epilepsy and neurological disorders. It offers implantable components, which include the RNS neurostimulator as well as depth and cortical strip leads. The firm's RNS System is designed for the treatment of medically refractory partial epilepsy and includes implantable and external products. The company was founded by Rebecca L. Kuhn, Frank M. Fischer on November 19, 1997 and is headquartered in Mountain View, CA.
| Q2 2025 | YOY Change | |
|---|---|---|
| Revenue | $23.52M | 22.1% |
| Gross Profit | $18.13M | 28.3% |
| Gross Margin | 77.09% | 3.7% |
| Market Cap | $365.38M | 68.0% |
| Market Cap / Employee | $1.99M | 0.0% |
| Employees | 184 | 7.6% |
| Net Income | -$8.65M | -15.1% |
| EBITDA | -$6.35M | -9.7% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q2 2025 | YOY Change | |
|---|---|---|
| Net Cash | $22.86M | 78.0% |
| Accounts Receivable | $13.55M | 20.6% |
| Inventory | 16.3 | 43.9% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $69.53M | -3.3% |
| Short Term Debt | $1.99M | 14.1% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -25.88% | 4.5% |
| Return On Invested Capital | -39.86% | -17.6% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$2.25M | 43.1% |
| Operating Free Cash Flow | -$2.09M | 46.5% |
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 21.13 | 33.92 | 46.24 | 15.03 | -0.70% |
| Price to Sales | 2.68 | 4.19 | 4.59 | 4.13 | 36.09% |
| Price to Tangible Book Value | 21.13 | 33.92 | 46.24 | 15.03 | -0.69% |
| Enterprise Value to EBITDA | -58.52 | -627.79 | -84.05 | -59.16 | 44.88% |
| Return on Equity | -214.5% | -189.4% | -128.5% | -176.9% | -7.93% |
| Total Debt | $73.50M | $73.34M | $73.15M | $71.52M | -2.91% |
NPCE earnings call for the period ending June 30, 2022.
NPCE earnings call for the period ending March 31, 2022.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
